Filing Details
- Accession Number:
- 0001179110-20-008423
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-23 16:08:33
- Reporting Period:
- 2020-07-21
- Accepted Time:
- 2020-07-23 16:08:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1235010 | Momenta Pharmaceuticals Inc | MNTA | Biological Products, (No Disgnostic Substances) (2836) | 043561634 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1716468 | M. Anthony Manning | C/O Momenta Pharmaceuticals, Inc. 301 Binney Street Cambridge MA 02142 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-07-21 | 194 | $34.67 | 14,523 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-07-21 | 1,745 | $34.69 | 12,778 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018.
- This transaction was executed in multiple trades at prices ranging from $34.25 to $34.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- This transaction was executed in multiple trades at prices ranging from $34.25 to $34.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Billionaire Hedge Funds
